Insulet Corp. (PODD) Operating Cash Flow
The operating cash flow for Insulet Corp. (PODD) is $569.30M with a period-over-period change of +32.30%. Operating cash flow is the cash generated by core business operations before capital expenditures.
PODD Operating Cash Flow Chart
Reported annual fiscal-period values; no daily interpolation.
PODD Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
Operating Cash Flow History
| Date | Operating Cash Flow | % Change |
|---|---|---|
| 2025 | $569.30M | +32.30% |
| 2024 | $430.30M | +195.33% |
| 2023 | $145.70M | +22.44% |
| 2022 | $119.00M | +274.74% |
| 2021 | ($68.10M) | (181.07%) |
| 2020 | $84.00M | (14.63%) |
| 2019 | $98.40M | +174.09% |
| 2018 | $35.90M | (13.08%) |
| 2017 | $41.30M | +159.57% |
| 2016 | $15.91M | +226.76% |
| 2015 | ($12.55M) | (240.72%) |
| 2014 | $8.92M | +166.43% |
| 2013 | $3.35M | +111.52% |
| 2012 | ($29.06M) | (14.17%) |
| 2011 | ($25.45M) | +28.56% |
| 2010 | ($35.63M) | +27.77% |
| 2009 | ($49.32M) | +40.29% |
| 2008 | ($82.61M) | (64.00%) |
| 2007 | ($50.37M) | (58.30%) |
| 2006 | ($31.82M) | (56.59%) |
| 2005 | ($20.32M) | (55.64%) |
| 2004 | ($13.06M) | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy